SGLT-2 inhibitors are of particular interest, as they have been shown to decrease heart disease mortality and symptom burden in numerous large randomized controlled trials, leading to the incorporation of these agents into routine clinical practice for patients with CHF. Here, SLC5A2 is linked to congestive heart failure.